Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
We view retatrutides significantly improved discontinuation rate and rates of dysesthesia as a positive that is likely to improve uptake when eventually commercialized. When asked about side effects, Custer said the drugs profile was broadly consistent with other GLP-1 medicines
Furthermore, retatrutide has demonstrated a remarkable ability to reduce liver fat content by up to 86% in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD), and shows promise in mitigating other cardiovascular risk factors
doi:10.1016/j.cmet.2016.02.005 Bartels RD, Kelly KM, Rothman AJ
Journal of Palliative Medicine
Harnedy PA, Parthsarathy V, McLaughlin CM, et al
Results are reported as the median (IQR) or mean (s.d.)
US$ 27.41
US$ 25.36
US$ 29.29
US$ 25.12
US$ 26.38
US$ 29.17
US$ 20.40
